论文部分内容阅读
目的研究不同剂量的紫杉醇联合固定剂量的顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法第１天甲组用紫杉醇１０５ｍｇ／ｍ２，乙组用紫杉醇１８０ｍｇ／ｍ２，两组第２～５天均用顺铂４０ｍｇ／ｍ２。应用紫杉醇前予抗过敏治疗，紫杉醇均用３ｈ的静脉滴注。结果两组均无完全缓解（ＣＲ）。甲组部分缓解（ＰＲ）３６４％（４／１１），初治病人为６０％（３／５），复治为１７％（１／６）。乙组ＰＲ２８６％（４／１４），初治为４０％（２／５），复治２２％（２／９）。中性粒细胞的抑制作用甲组轻于乙组，周围神经毒性亦低于乙组。其余不良反应两组相似。结论两种剂量的紫杉醇联合固定剂量的顺铂对初治晚期非小细胞肺癌均有效，但对复治病例疗效差，特别是１０５ｍｇ／ｍ２组。
Objective To investigate the clinical efficacy and adverse reactions of different doses of paclitaxel and fixed-dose cisplatin in the treatment of advanced non-small cell lung cancer. Methods On the first day of group A, paclitaxel was used at 105 mg/m2, group B was treated with paclitaxel at 180 mg/m2, and in group 2 to 5, cisplatin was used at 40 mg/m2. All antihypersensitivity treatments with paclitaxel were administered before and paclitaxel was administered intravenously over 3 hours. Results There was no complete remission (CR) in both groups. Partial remission (PR) was 36.4% (4/11) in group A, 60% (3/5) in untreated patients, and 17% (1/6) in retreatment. Group B PR28 6% (4/14), initial treatment was 40% (2/5), retreatment was 22% (2/9). The inhibitory effect of neutrophils in group A was lighter than that in group B, and the peripheral nerve toxicity was also lower than that in group B. The remaining adverse reactions were similar in both groups. Conclusion Both doses of paclitaxel combined with fixed dose of cisplatin are effective for the treatment of advanced non-small cell lung cancer, but the effect of retreatment is poor, especially in the 105mg/m2 group.